What exclusivity strategies has stelara used to delay competition?

Stelara (ustekinumab) has relied on a multi-pronged approach common to biologics to delay biosimilar competition. The key strategies are:

- Extensive patent portfolio around the product and its uses
- Patents covering the ustekinumab antibody itself (composition of matter), as well as various formulations, delivery methods, and methods of use (treatment of psoriasis, Crohn’s disease, psoriatic arthritis, etc.). This creates a dense patent thicket that biosimilar developers must navigate.

- Patent term extensions and regulatory data exclusivity
- Patent term extensions (where available) can push back the effective expiry of patent protection to account for regulatory review delays.
- Regulatory data exclusivity for biologics (in the U.S., commonly cited as 12 years of data exclusivity) can delay biosimilar approval even if patents expire. Pediatric exclusivity (an additional extension if pediatric studies are completed) can further extend market protection.

- Broad, ongoing patenting and renewal strategy
- Filing new or continuation/divisional patents around improvements, manufacturing processes, and additional uses to continually refresh protection as older patents approach expiry.

- Litigation and settlements to delay entry
- Janssen/J&J have pursued patent litigation against biosimilar applicants in multiple markets and, in some cases, reached settlements that postpone biosimilar entry for defined periods. This is a common tactic to extend the window before competition can launch.

- Protection of manufacturing know-how and trade secrets
- Beyond what’s disclosed in patents, manufacturing processes and other confidential know-how can create barriers to entry, especially for complex biologics where process details matter for biosimilarity.

- Global, jurisdictional strategy
- Filing and enforcing patent rights across major markets (US, EU, Asia, etc.) to secure overlapping protections and maximize or preserve exclusivity in key regions.

If you’d like, I can pull region-specific details (US vs EU) on current exclusivity durations, patent families, and any notable biosimilar litigation or settlements involving Stelara.